Extravasation of Diagnostic and Therapeutic Materials

Explore clinical trials studying Extravasation of Diagnostic and Therapeutic Materials. Study availability and eligibility vary by location and protocol.

16 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

Extravasation of Diagnostic and Therapeutic Materials trial results

Completed

Transgender, Silicone and Blood Smear

NCT02580760

Conditions: Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Extravasation of Diagnostic and Therapeutic Materials, +11 more
Locations: Hôpitaux Universitaires Paris-Nord Val de Seine, site Bichat Paris, France

View Trial Details

Completed

Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration

NCT00333736

Conditions: Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Chemically-Induced Disorders, +20 more
Locations: Maple Leaf Medical Clinic Toronto, Ontario, Canada

View Trial Details

Completed

Study to Evaluate the Need of Needle Change for Application of Intramuscular, Subcutaneous and Intradermal Injection.

NCT01271608

Conditions: Behavior, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, +10 more
Locations: M Boi Mirim Hospital São Paulo, Brazil

View Trial Details

Completed

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

NCT00365781

Conditions: Chemically-Induced Disorders, Diabetes Mellitus, Diabetes Mellitus, Type 2, +10 more
Locations: Therapeutics Clinical Research San Diego, California, United States

View Trial Details

Active, Not Recruiting

Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.

NCT07703748

Conditions: Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Chemically-Induced Disorders, +21 more
Locations: Hospital Universitario de Burgos Burgos, Spain

View Trial Details

Active, Not Recruiting

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

NCT06970223

Conditions: Blood-Borne Infections, Chemically-Induced Disorders, Communicable Diseases, +17 more
Locations: GSK Investigational Site Long Beach, California, United States

View Trial Details

Extravasation of Diagnostic and Therapeutic Materials

Extravasation of Diagnostic and Therapeutic Materials trial results

Transgender, Silicone and Blood Smear

Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration

Study to Evaluate the Need of Needle Change for Application of Intramuscular, Subcutaneous and Intradermal Injection.

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Related conditions